• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nektar Therapeutics

    3/15/24 4:18:49 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTR alert in real time by email
    SC 13G 1 d800776dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    NEKTAR THERAPEUTICS

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    640268108

    (CUSIP Number)

    March 6, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 640268108       13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover GP II, LLC

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     20,046,350 (1)(2)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     20,046,350 (1)(2)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,046,350 (1)(2)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9% (2)(3)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     OO

     

    (1)

    These securities are held of record by TCG Crossover II (as defined in Item 2(a) below). TCG Crossover GP II (as defined in Item 2(a) below) is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (i) 3,000,000 shares of Common Stock (as defined in Item 2(d) below) of the Issuer (as defined in Item 1(a) below) and (ii) 17,046,350 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants (as defined and described in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on March 4, 2024). This total excludes 7,953,650 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants because the Pre-Funded Warrants may not be exercised to the extent that doing so would result in the holder of the Pre-Funded Warrants (together with the holder’s affiliates and any other persons acting as a group together with the holder or any of the holder’s affiliates) beneficially owning more than 9.99% of the shares of Common Stock then outstanding immediately after giving effect to such exercise (the “Beneficial Ownership Limitation”).

    (3)

    Based on 183,617,817 shares of Common Stock outstanding as of February 27, 2024, as reported by the Issuer in its Annual Report on Form 10-K filed with the Commission on March 5, 2024 (the “Form 10-K”), plus 17,046,350 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


    CUSIP No. 640268108       13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     TCG Crossover Fund II, L.P.

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     20,046,350 (1)(2)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     20,046,350 (1)(2)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,046,350 (1)(2)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9% (2)(3)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     PN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (i) 3,000,000 shares of Common Stock held of record by TCG Crossover II and (ii) 17,046,350 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II. This total excludes 7,953,650 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants as a result of the Beneficial Ownership Limitation.

    (3)

    Based on 183,617,817 shares of Common Stock outstanding, as disclosed by the Issuer in its Form 10-K, plus 17,046,350 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


    CUSIP No. 640268108       13G

     

     1.   

     NAMES OF REPORTING PERSONS

     

     Chen Yu

     2.  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     (a) ☐  (b) ☒

     

     3.  

     SEC USE ONLY

     

     4.  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

     SOLE VOTING POWER

     

     0

       6.   

     SHARED VOTING POWER

     

     20,046,350 (1)(2)

       7.   

     SOLE DISPOSITIVE POWER

     

     0

       8.   

     SHARED DISPOSITIVE POWER

     

     20,046,350 (1)(2)

     9.   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     20,046,350 (1)(2)

    10.  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

     

     ☐

    11.  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     9.9% (2)(3)

    12.  

     TYPE OF REPORTING PERSON (see instructions)

     

     IN

     

    (1)

    These securities are held of record by TCG Crossover II. TCG Crossover GP II is the general partner of TCG Crossover II and may be deemed to have voting, investment, and dispositive power with respect to these securities. Chen Yu is the sole managing member of TCG Crossover GP II and may be deemed to share voting, investment and dispositive power with respect to these securities.

    (2)

    Consists of (i) 3,000,000 shares of Common Stock held of record by TCG Crossover II and (ii) 17,046,350 shares of Common Stock, issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II. This total excludes 7,953,650 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants as a result of the Beneficial Ownership Limitation.

    (3)

    Based on 183,617,817 shares of Common Stock outstanding, as disclosed by the Issuer in its Form 10-K, plus 17,046,350 shares of Common Stock issuable upon exercise of certain Pre-Funded Warrants held of record by TCG Crossover II.


    CUSIP No. 640268108       13G

     

    Item 1(a).

    Name of Issuer:

    Nektar Therapeutics (the “Issuer”).

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    455 Mission Bay Boulevard South

    San Francisco, California 94158

     

    Item 2(a).

    Name of Person Filing:

    This joint statement on Schedule 13G is being filed by TCG Crossover Fund II, L.P. (“TCG Crossover II”), TCG Crossover GP II, LLC (“TCG Crossover GP II” and together with TCG Crossover II, the “Reporting Entities”) and Chen Yu (the “Reporting Individual”). The Reporting Entities and the Reporting Individual are collectively referred to as the “Reporting Persons.” The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13G. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached to this Statement as Exhibit 1. Other than those securities reported herein as being held directly by such Reporting Person, each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person’s pecuniary interest therein.

     

    Item 2(b)

    Address of Principal Business Office, or if None, Residence:

    The address of the principal business office of each Reporting Person is 705 High St., Palo Alto, CA 94301.

     

    Item 2(c).

    Citizenship:

    TCG Crossover GP II is a limited liability company organized under the laws of the State of Delaware. TCG Crossover II is a limited partnership organized under the laws of the State of Delaware. The Reporting Individual is a citizen of the United States of America.

     

    Item 2(d).

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share (“Common Stock”).

     

    Item 2(e).

    CUSIP Number:

    640268108

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    CUSIP No. 640268108       13G

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (b)

    Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote

    See Row 5 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (ii)

    Shared power to vote or to direct the vote

    See Row 6 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iii)

    Sole power to dispose or to direct the disposition of

    See Row 7 of the cover page for each Reporting Person and the corresponding footnotes.*

     

      (iv)

    Shared power to dispose or to direct the disposition of

    See Row 8 of the cover page for each Reporting Person and the corresponding footnotes.*

     

    *

    Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person.

    Under certain circumstances set forth in the limited partnership agreement of TCG Crossover II and the limited liability company agreement of TCG Crossover GP II, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.


    CUSIP No. 640268108       13G

     

    Item 9.

    Notice of Dissolution of the Group.

    Not applicable.

     

    Item 10.

    Certifications.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11 promulgated under the Act.

    Material to be Filed as Exhibits.

    Exhibit 1 – Joint Filing Agreement.


    CUSIP No. 640268108       13G

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: March 15, 2024

     

    TCG Crossover Fund II, L.P.
    By:   TCG Crossover GP II, LLC
    Its:   General Partner
    By:  

    /s/ Craig Skaling

      Authorized Signatory
    TCG Crossover GP II, LLC
    By:  

    /s/ Craig Skaling

      Authorized Signatory

    /s/ Craig Skaling, as attorney-in-fact for Chen Yu

    Chen Yu
    Get the next $NKTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTR

    DatePrice TargetRatingAnalyst
    6/24/2025$60.00 → $100.00Buy
    BTIG Research
    6/24/2025$6.50 → $120.00Buy
    H.C. Wainwright
    4/11/2025$2.00Hold → Buy
    Jefferies
    3/14/2025$6.00Perform → Outperform
    Oppenheimer
    1/8/2025$4.00Buy
    B. Riley Securities
    12/10/2024$6.50Buy
    H.C. Wainwright
    11/4/2024$7.00Overweight
    Piper Sandler
    9/30/2024$4.00Buy
    BTIG Research
    More analyst ratings

    $NKTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on Nektar Therapeutics with a new price target

    BTIG Research reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $100.00 from $60.00 previously

    6/24/25 2:02:55 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Nektar Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Nektar Therapeutics with a rating of Buy and set a new price target of $120.00 from $6.50 previously

    6/24/25 1:36:32 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics upgraded by Jefferies with a new price target

    Jefferies upgraded Nektar Therapeutics from Hold to Buy and set a new price target of $2.00

    4/11/25 8:15:16 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief R&D Officer Zalevsky Jonathan sold $7,177 worth of shares (10,712 units at $0.67), decreasing direct ownership by 3% to 305,892 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    5/21/25 8:08:34 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Wilson Mark Andrew sold $6,697 worth of shares (9,996 units at $0.67), decreasing direct ownership by 3% to 314,296 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    5/21/25 8:07:50 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Robin Howard W sold $15,549 worth of shares (23,208 units at $0.67), decreasing direct ownership by 2% to 1,063,693 units (SEC Form 4)

    4 - NEKTAR THERAPEUTICS (0000906709) (Issuer)

    5/21/25 8:07:02 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    SEC Filings

    View All

    SEC Form S-8 filed by Nektar Therapeutics

    S-8 - NEKTAR THERAPEUTICS (0000906709) (Filer)

    8/7/25 7:46:12 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    8/7/25 4:26:08 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Nektar Therapeutics

    8-K - NEKTAR THERAPEUTICS (0000906709) (Filer)

    7/1/25 4:44:06 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment

    USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure on cancer research efforts in the United States, but private investment is helping to fill the gap, with oncology ventures securing hundreds of millions in funding so far in 2025. The Senate's recent restoration of $15 million for the Pancreatic Cancer Research Program (PCARP) was a win, yet its earlier elimination underscored the fragility of public support. Against this backdrop, investors are zeroing in on companies with standout science, solid pipelines, and clear regulatory strategies, including Onc

    8/14/25 12:22:00 PM ET
    $FATE
    $INO
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Nektar Therapeutics Reports Second Quarter 2025 Financial Results

    SAN FRANCISCO, Aug. 7, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the second quarter ended June 30, 2025. Cash and investments in marketable securities on June 30, 2025 were $175.9 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities at June 30, 2025 do not include $107.5 million of approximate net proceeds from the secondary offering closed on July 2, 2025.  With the net proceeds from the secondary offering, we expect our cash and investments in marketable securities to support our

    8/7/25 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. T

    7/31/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Leadership Updates

    Live Leadership Updates

    View All

    DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer

    Executive with Strong Track Record in Advancing Pipelines Through Clinical Development DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, announced today the appointment of Lorianne Masuoka, M.D. as Chief Medical Officer. Dr. Masuoka is a board-certified neurologist with more than 25 years of experience and a successful track record of managing clinical programs from early stage to drug approvals and strategic alliances. "We are delighted to have Lorianne join our executive leadership team," said Rick Pauls, DiaMedica's President and Chief Executive Officer. "Sh

    1/22/24 8:23:00 AM ET
    $DMAC
    $MRNS
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BigHat Biosciences Appoints Rob Chess, Serial Entrepreneur, to its Board of Directors

    BigHat Biosciences, a biotechnology company designing safer, more effective next-generation antibody therapies for patients using machine learning and synthetic biology, today announced that Rob Chess has been elected to BigHat's board of directors. Rob brings valuable experience in corporate biotech leadership and business strategy, from having led innovative and diverse teams from inception to successful exits to serving on the boards of multiple private and public life sciences companies. "We look forward to leveraging Rob's deep expertise in drug discovery and development to accelerate our work creating better antibody therapies for patients," said Mark DePristo, PhD., BigHat's CEO and

    5/11/22 8:01:00 AM ET
    $NKTR
    $TWST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.

    SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today announced it has appointed Diana M. Brainard, M.D., as an independent director to its Board of Directors. Dr. Brainard brings over two decades of experience working in the healthcare sector and academia to Nektar. She currently serves as Chief Executive Officer (CEO) of AlloVir, Inc., a leading late clinical stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. "We are very ple

    11/15/21 8:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 12:17:04 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nektar Therapeutics

    SC 13G/A - NEKTAR THERAPEUTICS (0000906709) (Subject)

    11/14/24 9:18:10 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Nektar Therapeutics

    SC 13G - NEKTAR THERAPEUTICS (0000906709) (Subject)

    3/15/24 4:18:49 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTR
    Financials

    Live finance-specific insights

    View All

    Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

    SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: https://ir.nektar.com/. T

    7/31/25 6:00:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

    Achieved statistical significance on primary endpoint at week 16 for mean percent change in EASI score from baseline for all rezpegaldesleukin arms versus placebo Achieved statistical significance for key secondary endpoints at week 16 of disease reduction, including EASI-75, EASI-90, Itch NRS, vIGA-AD and BSA Rapid onset of EASI reduction and magnitude of itch improvement show potential differentiation of this novel regulatory T-cell mechanism as a first and best-in-class immune-modulator Robust dose-dependent reduction of inflammatory biomarkers in atopic dermatitis including TARC/CCL17, periostin, MDC/CCL22, and IL-19 Safety profile consistent with previously reported results Data expec

    6/24/25 7:30:00 AM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nektar Therapeutics Reports First Quarter 2025 Financial Results

    SAN FRANCISCO, May 8, 2025 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) today reported financial results for the first quarter ended March 31, 2025. Cash and investments in marketable securities on March 31, 2025 were $220.7 million as compared to $269.1 million on December 31, 2024. Nektar's cash and marketable securities are expected to support strategic development activities and operations into the fourth quarter of 2026. "We are on track to report topline data in June from the Phase 2 study of rezpegaldesleukin in atopic dermatitis," said Howard W. Robin, President a

    5/8/25 4:15:00 PM ET
    $NKTR
    Biotechnology: Pharmaceutical Preparations
    Health Care